How Do Drugs Get Approved (and Fast-Tracked) by the FDA?
Read time: 5 minutes.
This is Part 3 in our series on how drugs get approved to treat lung cancer.
Read time: 5 minutes.
This is Part 3 in our series on how drugs get approved to treat lung cancer.
Read time: 6 minutes.
This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are important for new drug development.
Read time: 3 minutes.
This is Part 1 in a 3-part series explaining how new drugs and treatments get approved to treat lung cancer. Parts 2 and 3 will be published in the coming weeks.
Have you ever wondered how a new medicine or drug to treat lung cancer is brought to the people who need it? That’s what clinical trials help us do.
Read time: 3 minutes.
One of LUNGevity’s two flagship survivorship events, the International Lung Cancer Survivorship Conference (ILCSC), is being held virtually September 20 – 21, 2024. This is a free, online event that allows people with lung cancer and caregivers from around the world to join from the comfort of their own homes and hear from a star-studded lineup of lung cancer experts discussing the latest advances in research and treatment.
Read time: 2 minutes.
Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with researchers behind the scenes and get involved in designing clinical trials.
Read time: 2 minutes
Integrative oncology adds holistic approaches—such as acupuncture, nutrition, exercise, and mindfulness—into a treatment plan. Research shows these interventions can have a tremendous impact on people going through lung cancer treatment and their quality of life. Unfortunately, they are also topics riddled with myths and falsehoods.
LUNGevity spoke to an expert to help sort out the facts from the fiction.
On April 18, 2024, the US Food and Drug Administration (FDA) announced the approval of alectinib to treat patients after surgical removal of ALK-positive non-small cell lung cancer (NSCLC).
The approval is supported by data from the phase 3 ALINA trial, which showed that treating patients with alectinib reduced the risk of disease recurrence by 76% compared to treating them with chemotherapy.
Alectinib is approved for use in patients with completely resected stage IB to IIIA ALK-positive NSCLC whose tumors are at least 4 cm wide.
This March, LUNGevity Foundation partnered with CURE for their “Speaking Out” video series, inviting Amy Moore, PhD, vice president of global engagement and patient partnerships at LUNGevity Foundation, to discuss recent chemotherapy shortages. During the interview, Dr.
In the past five years, the lung cancer community has seen an astonishing number of new treatments. As our understanding of lung cancer has deepened, the older treatment approaches have also become more effective and efficient.
These options are fantastic steps toward improving the overall survival and quality of life for people living with lung cancer, but it can be difficult for patients and caregivers to keep track of the new drug treatments and scientific advancements.